Silmitasertib (CX-4945)

silmitasertib · Senhwa Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Silmitasertib (CX-4945), covering 2023-08-14 to 2025-05-20. Get the full timeline:

Most recent: Clinical Trial Update: Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) [Phase 1]

See pricing